Promiliad, Spero Therapeutics, University of Connecticut deal Posted on January 25, 2016 at 12:48 am.Written by Spero Therapeutics Post navigation Spero Therapeutics Licenses Dihydrofolate Reductase Inhibitors from Promiliad BiopharmaSpero closes $30M series B round
